Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)

Market Cap	5.37B +128.0%
Revenue (ttm)	615.39M +23.0%
Net Income	44.78M +6.6%
EPS	0.37 +6.6%
Shares Out	120.00M
PE Ratio	120.02
Forward PE	n/a
Dividend	0.10 (0.22%)
Ex-Dividend Date	n/a

Volume	3,907,400
Average Volume	3,756,146
Open	45.33
Previous Close	45.78
Day's Range	44.07 - 45.33
52-Week Range	15.54 - 81.88
Beta	0.30
RSI	41.22
Earnings Date	Apr 25, 2026

About SHE:300584

Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company’s products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for injection; voglibose tablets, lansoprazole enteric-coated tablets, amlodipine besylate tablets, and glucosamine sulfate effervescent tablets/granules; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2003
• Employees: 548
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300584

Financial Performance

In 2024, SHE:300584's revenue was 504.36 million, a decrease of -2.60% compared to the previous year's 517.83 million. Earnings were 40.22 million, an increase of 10.75%.